BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants

British Medical Journal investigation focuses mainly on Boehringer’s direct thrombin inhibitor Pradaxa, but also suggests that all novel anticoagulants could benefit from testing to ensure the right anticoagulant dose is being given, for safety’s sake.